Investors
News Releases
- April 29, 2024Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- April 2, 2024Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- April 1, 2024Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- March 20, 2024Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- February 27, 2024Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- February 14, 2024Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- January 30, 2024Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
- January 24, 2024Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
- December 11, 2023Annovis Bio to Participate in the 139th Yale CEO Summit
- December 5, 2023Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top